erythromycin(redirected from erythromycin base)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Akne-Mycin, A/T/S, E-Glades, E-Solve 2, Erycette, Eryderm, Erygel, Sans-Acne (CA), Stiemycin (UK)
Pharmacologic class: Macrolide
Therapeutic class: Anti-infective
Pregnancy risk category B
Binds with 50S subunit of susceptible bacterial ribosomes, suppressing protein synthesis in bacterial cells and causing cell death
Capsules (delayed-release): 250 mg
Ointment (ophthalmic): 0.5%
Tablets: 250 mg, 500 mg
Tablets (delayed-release, enteric-coated): 250 mg, 333 mg, 500 mg
Tablets (particles in tablets): 333 mg, 500 mg
Oral suspension: 200 mg/5 ml, 400 mg/5 ml
Powder for suspension: 100 mg/2.5 ml, 200 mg/5 ml, 400 mg/5 ml Tablets: 400 mg
Powder for injection: 500 mg, 1 g
Tablets (film-coated): 250 mg, 500 mg
⊘Indications and dosages
➣ Pelvic inflammatory disease
Adults: 500 mg (base) I.V. q 6 hours for 3 days, then 250 mg (base, estolate, or stearate) or 400 mg (ethylsuccinate) q 6 hours for 7 days
Adults: 500 mg (base, estolate, or stearate) P.O. q.i.d. for 14 days
➣ Most upper and lower respiratory tract infections; otitis media; skin infections; Legionnaires' disease
Adults: 250 mg P.O. q 6 hours, or 333 mg P.O. q 8 hours, or 500 mg P.O. q 12 hours (base, estolate, or stearate); or 400 mg P.O. q 6 hours or 800 mg P.O. q 12 hours (ethylsuccinate); or 250 to 500 mg I.V. (up to 1 g) q 6 hours (gluceptate or lactobionate)
Children: 30 to 50 mg/kg/day (base, estolate, ethylsuccinate, or lactobionate) I.V. or P.O., in divided doses q 6 hours when giving I.V. and q 6 to 8 hours when giving P.O. Maximum dosage is 2 g/day for base or estolate, 3.2 g/day for ethylsuccinate, and 4 g/day for lactobionate.
➣ Intestinal amebiasis
Adults: 250 mg (base, estolate, or stearate) or 400 mg (ethylsuccinate) P.O. q 6 hours for 10 to 14 days
Children: 30 to 50 mg/kg/day (base, estolate, ethylsuccinate, or stearate) P.O. in divided doses over 10 to 14 days
➣ Prophylaxis of ophthalmia neonatorum caused by Neisseria gonorrhoeae or Chlamydia trachomatis
Neonates: 0.5- to 1-cm ribbon of ointment into each lower conjunctival sac once
➣ Treatment of conjunctivitis of the newborn caused by susceptible organisms
Neonates: 50 mg/kg/day (ethylsuccinate) P.O. in four divided doses for at least 14 days
Children: 40 to 50 mg/kg/day (estolate preferred) P.O. in four divided doses for 14 days
➣ Pneumonia of infancy
Infants: 50 mg/kg/day (estolate or ethylsuccinate) P.O. in four divided doses for at least 3 weeks
Adults and children older than age 12: 2% ointment, gel, or solution applied topically b.i.d.
e·ryth·ro·my·cin(ĕ-rith'rō-mī'sin), Avoid the mispronunciation ĕ-rith-rō-mī'ă-sin.
erythromycin/eryth·ro·my·cin/ (-mi´sin) a broad-spectrum antibiotic produced by Streptomyces erythreus; used against gram-positive bacteria and certain gram-negative bacteria, spirochetes, some rickettsiae, Entamoeba, and Mycoplasma pneumoniae; used in the form of the gluceptate, lactobionate, stearate, and other salts.
e·ryth·ro·my·cin(ĕ-rith'rō-mī'sin) Avoid the mispronunciation ĕ-rith-rō-m'ă-sin.
erythromycinAn antibiotic of the macrolide class with an action similar to that of the tetracyclines. It binds to the RIBOSOMES in bacterial cells and interferes with the synthesis of protein. Oral erythromycin extends cardiac repolarization. It is metabolized by cytochrome P-450 3A isoenzymes and drugs such as nitroimidazole antifungals, verapamil, diltiazen and troleandomycin that inhibit CTP3A can increase the risk of ventricular arrhythmias and sudden death. Erythromycin is on the WHO official list. Brand names are Arpimicin, Erymax, Erymin, Erythrocin, Erythroped, Tiloryth, and, formulated with other drugs for external use only, Benzamycin, Isotrexin and Zineryl.
erythromycinan antibiotic produced by a strain of STREPTOMYCES that inhibits protein synthesis, particularly in organisms which are Gram-positive (see GRAM'S STAIN).
erythromycinmacrolide; antimicrobial agent with similar spectrum of action to penicillin; effective against Gram-positive bacteria, including some penicillin-resistant staphylococci; indicated for treatment of cellulitis, impetigo and erysipelas in penicillin-sensitive individuals; dose = 250-500 mg orally every 6 hours
e·ryth·ro·my·cin(ĕ-rith'rō-mī'sin) Avoid the mispronunciation ĕ-rith-rō-mī'ă-sin.
n an antibiotic produced by a strain of
S. erythroeus, only slightly effective against β-hemolytic streptococci (viridans group), and upper and lower respiratory tract, skin, and soft tissue infections of mild to moderate severity. It is no longer recommended by the American Heart Association and the American Dental Association for treatment of bacterial endocarditis in patients hypersensitive to penicillin.
drug class: macrolide antibiotic;
action: binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis;
uses: infections caused by
N. gonorrhoeae; mild to moderate respiratory tract, skin, soft tissue infections caused by
S. pneumoniae, C. diphtheriae, B. pertussis; syphilis; Legionnaire's disease; H. influenzae.